MedTrace Logo

Open-Label Lesinurad Monotherapy Extension Study in Gout

NCT01650246 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2016-05-26

Study results available
· View outcomes & findings →

Summary

This study will assess the serum uric acid lowering effects and safety of lesinurad over a long-term timeframe.

Conditions

Interventions

DRUG

lesinurad

Tablets, 400 mg QD

Sponsors & Collaborators

  • Ardea Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Chris Storgard, MD · Ardea Biosciences, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-04-30
Completion
2014-08-31

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Germany
  • New Zealand
  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01650246 on ClinicalTrials.gov